Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 109
Filtrar
1.
BMC Public Health ; 24(1): 2282, 2024 Aug 22.
Artículo en Inglés | MEDLINE | ID: mdl-39174935

RESUMEN

OBJECTIVE: To analyse hospital case fatality and mortality related to Chagas disease (CD) in Brazil, 2000-2019. METHOD: This is a mixed ecological study with spatial and temporal trends, based on national population data from the Brazilian Ministry of Health - hospital admissions (HA) and death certificates (DC). Records with CD as a primary or secondary cause of death in HA and/or as an underlying or associated cause of death in DC were evaluated. Temporal trends were analysed by Joinpoint regression and the spatial distribution of age- and gender-adjusted rates, spatial moving averages, and standardized morbidity ratios. RESULTS: There were a total of 4,376 HA due to CD resulting in death in Brazil, with a hospital case fatality rate of 0.11/100,000 inhabitants. The Southeast region had the highest rate (63.9%, n = 2,796; 0.17/100,000 inhabitants). The general trend for this indicator in Brazil is upwards (average annual percentage change [AAPC] 7.5; 95% confidence interval [CI] 5.3 to 9.9), with increases in the North, Northeast and Southeast regions. During the same period 122,275 deaths from CD were registered in DC, with a mortality rate of 3.14/100,000 inhabitants. The highest risk of CD-related death was found among men (relative risk [RR] 1.27) and Afro-Brazilians (RR 1.63). There was a downward trend in CD mortality in the country (AAPC - 0.7%, 95%CI -0.9 to -0.5), with an increase in the Northeast region (AAPC 1.1%, 95%CI 0.6 to 1.6). Municipalities with a very high Brazilian Deprivation Index tended to show an increase in mortality (AAPC 2.1%, 95%CI 1.6 to 2.7), while the others showed a decrease. CONCLUSION: Hospital case fatality and mortality due to CD are a relevant public health problem in Brazil. Differences related to gender, ethnicity, and social vulnerability reinforce the need for comprehensive care, and to ensure equity in access to health in the country. Municipalities, states, and regions with indicators that reveal higher morbidity and mortality need to be prioritized.


Asunto(s)
Enfermedad de Chagas , Mortalidad Hospitalaria , Humanos , Brasil/epidemiología , Enfermedad de Chagas/mortalidad , Masculino , Femenino , Adulto , Persona de Mediana Edad , Mortalidad Hospitalaria/tendencias , Adolescente , Anciano , Adulto Joven , Preescolar , Niño , Lactante , Análisis Espacio-Temporal , Recién Nacido
2.
Mem Inst Oswaldo Cruz ; 119: e240057, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38958341

RESUMEN

Chagas disease is a tropical neglected disease that affects millions of people worldwide, still demanding a more effective and safer therapy, especially in its chronic phase which lacks a treatment that promotes substantial parasitological cure. The technical note of Romanha and collaborators published in 2010 aimed establish a guideline with the set of minimum criteria and decision gates for the development of new agents against Trypanosoma cruzi with the focus on developing new antichagasic drugs. In this sense, the present review aims to update this technical note, bringing the state of the art and new advances on this topic in recent years.


Asunto(s)
Enfermedad de Chagas , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Tripanocidas , Trypanosoma cruzi , Enfermedad de Chagas/tratamiento farmacológico , Tripanocidas/farmacología , Tripanocidas/uso terapéutico , Animales , Trypanosoma cruzi/efectos de los fármacos , Humanos , Desarrollo de Medicamentos
3.
Sci Rep ; 14(1): 8208, 2024 04 08.
Artículo en Inglés | MEDLINE | ID: mdl-38589582

RESUMEN

To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC). PEACH study was a single-center, superiority randomized clinical trial of exercise training versus no exercise (control). The sample comprised Chagas disease patients with CCC, left ventricular ejection fraction < 45%, without or with HF symptoms (CCC stages B2 or C, respectively). QoL was assessed at baseline, after three months, and at the end of six months of follow-up using the SF-36 questionnaire. Patients randomized for the exercise group (n = 15) performed exercise training (aerobic, strength and stretching exercises) for 60 min, three times a week, during six months. Patients in the control group (n = 15) were not provided with a formal exercise prescription. Both groups received identical nutritional and pharmaceutical counseling during the study. Longitudinal analysis of the effects of exercise training on QoL, considering the interaction term (group × time) to estimate the rate of changes between groups in the outcomes (represented as beta coefficient), was performed using linear mixed models. Models were fitted adjusting for each respective baseline QoL value. There were significant improvements in physical functioning (ß = + 10.7; p = 0.02), role limitations due to physical problems (ß = + 25.0; p = 0.01), and social functioning (ß = + 19.2; p < 0.01) scales during the first three months in the exercise compared to the control group. No significant differences were observed between groups after six months. Exercise-based cardiac rehabilitation provided short-term improvements in the physical and mental aspects of QoL of patients with CCC.Trial registration: ClinicalTrials.gov Identifier: NCT02517632; August 7, 2015.


Asunto(s)
Rehabilitación Cardiaca , Cardiomiopatía Chagásica , Insuficiencia Cardíaca , Humanos , Rehabilitación Cardiaca/métodos , Calidad de Vida , Cardiomiopatía Chagásica/terapia , Volumen Sistólico , Función Ventricular Izquierda , Terapia por Ejercicio/métodos , Ejercicio Físico , Infección Persistente
4.
Int J Obes (Lond) ; 48(2): 254-262, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37932408

RESUMEN

BACKGROUND: Comorbidities such as obesity, hypertension, and diabetes are associated with COVID-19 development and severity, probably due to immune dysregulation; however, the mechanisms underlying these associations are not clear. The immune signatures of hypertensive patients with obesity with COVID-19 may provide new insight into the mechanisms of immune dysregulation and progression to severe disease in these patients. METHODS: Hypertensive patients were selected prospectively from a multicenter registry of adults hospitalized with COVID-19 and stratified according to obesity (BMI ≥ 30 kg/m²). Clinical data including baseline characteristics, complications, treatment, and 46 immune markers were compared between groups. Logistic regression was performed to identify variables associated with the risk of COVID-19 progression in each group. RESULTS: The sample comprised 213 patients (89 with and 124 without obesity). The clinical profiles of patients with and without obesity differed, suggesting potential interactions with COVID-19 severity. Relative to patients without obesity, patients with obesity were younger and fewer had cardiac disease and myocardial injury. Patients with obesity had higher EGF, GCSF, GMCSF, interleukin (IL)-1ra, IL-5, IL-7, IL-8, IL-15, IL-1ß, MCP 1, and VEGF levels, total lymphocyte counts, and CD8+ CD38+ mean fluorescence intensity (MFI), and lower NK-NKG2A MFI and percentage of CD8+ CD38+ T cells. Significant correlations between cytokine and immune cell expression were observed in both groups. Five variables best predicted progression to severe COVID-19 in patients with obesity: diabetes, the EGF, IL-10, and IL-13 levels, and the percentage of CD8+ HLA-DR+ CD38+ cells. Three variables were predictive for patients without obesity: myocardial injury and the percentages of B lymphocytes and HLA-DR+ CD38+ cells. CONCLUSION: Our findings suggest that clinical and immune variables and obesity interact synergistically to increase the COVID-19 progression risk. The immune signatures of hypertensive patients with and without obesity severe COVID-19 highlight differences in immune dysregulation mechanisms, with potential therapeutic applications.


Asunto(s)
COVID-19 , Diabetes Mellitus , Hipertensión , Adulto , Humanos , Linfocitos T CD8-positivos , COVID-19/complicaciones , COVID-19/metabolismo , Factor de Crecimiento Epidérmico/metabolismo , Factor A de Crecimiento Endotelial Vascular , Antígenos HLA-DR/metabolismo , Hipertensión/complicaciones , Hipertensión/epidemiología , Hipertensión/metabolismo , Obesidad/complicaciones , Obesidad/metabolismo
5.
Mem. Inst. Oswaldo Cruz ; 119: e240057, 2024. graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1564817

RESUMEN

Chagas disease is a tropical neglected disease that affects millions of people worldwide, still demanding a more effective and safer therapy, especially in its chronic phase which lacks a treatment that promotes substantial parasitological cure. The technical note of Romanha and collaborators published in 2010 aimed establish a guideline with the set of minimum criteria and decision gates for the development of new agents against Trypanosoma cruzi with the focus on developing new antichagasic drugs. In this sense, the present review aims to update this technical note, bringing the state of the art and new advances on this topic in recent years.

6.
Rev Soc Bras Med Trop ; 56: 0389, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38088665

RESUMEN

The increase in inflammatory markers associated with persistent chronic fibrosing myocarditis, a characteristic of chronic Chagas disease, can result in a reduction in inspiratory muscle strength (IMS) in Chagas cardiomyopathy (CC). However, literature in this field is still scarce. This review aimed to map and summarize the evidence regarding IMS in patients with CC. The inclusion criteria included reports with adult participants with a CC diagnosis, with or without heart failure (HF). The core concept examined was the maximum inspiratory pressure evaluated in the untrained and trained groups in the pre-training period. The context was open, including but not limited to hospitals and health centers. Two authors independently identified eligible studies and extracted the data. Descriptive synthesis was used as the primary strategy for analyzing the results. Nine studies (five clinical trials, three cross-sectional, and one cohort) were included. The CC classification differed among the studies, with no mention of HF in five and no CC staging specification in six. IMS was assessed using a manovacuometer, and only six studies analyzed and interpreted the data concerning the predicted values. The CC population with HF appeared to have impaired IMS. All studies involved only Brazilian volunteers. In conclusion, randomized clinical trials evaluating IMS and the effects of inspiratory muscle training need to be conducted to better understand the prevalence and risk of inspiratory muscle weakness in the CC population, as well as the effects of training. Such studies should be conducted at different stages of CC in different populations and countries.


Asunto(s)
Cardiomiopatía Chagásica , Adulto , Humanos , Estudios Transversales , Fuerza Muscular/fisiología , Enfermedad Crónica , Brasil , Músculos Respiratorios
8.
J Clin Med ; 12(23)2023 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-38068433

RESUMEN

(1) Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Although cardiovascular and NAFLD risk factors overlap, an independent association between these conditions may exist. Hepatic and cardiac fibrosis are important markers of mortality, but the correlation between these markers in patients with NAFLD has not been well studied. Our main objective was to determine the degree of myocardial fibrosis in patients with NAFLD and its correlation with the severity of liver fibrosis. (2) Methods: In this cross-sectional study, patients with NAFLD were allocated to two groups according to the stage of liver fibrosis assessed using MRI: no or mild fibrosis (F0-F1) and significant fibrosis (F2-F4). Framingham risk scores were calculated to evaluate cardiovascular risk factors, and patients underwent multiparametric cardiac and abdominal MRIs. (3) Results: The sample comprised 44 patients (28 with no or mild liver fibrosis and 16 with significant liver fibrosis). The mean age was 57.9 ± 12 years, and 41% were men. Most patients had high cardiac risk factors and carotid disease. Relative to patients with no or mild liver fibrosis, those with significant fibrosis had a higher median calcium score (p = 0.05) and increased myocardial extracellular volume (ECV; p = 0.02). Liver fibrosis correlated with cardiac fibrosis, represented by the ECV (r = 0.49, p < 0.001). The myocardial ECV differentiated patients with and without significant liver fibrosis (AUC = 0.78). (4) Conclusion: This study showed that diffuse myocardial fibrosis is associated with liver fibrosis in patients with NAFLD.

9.
Rev Soc Bras Med Trop ; 56: 0506, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38126377

RESUMEN

Chagas disease (CD) remains one of the most significant endemic diseases in Latin America. Approximately 30% of individuals with CD develop the cardiac form, the main determinant of morbidity and mortality, which is characterized by typical electrocardiogram (ECG) changes caused by chronic chagasic cardiopathy (CCC). This review accentuates to how crucial it is for research teams and reference centers that treat patients with CD to standardize ECG in CCC. This was a non-systematic review of the literature. ECG is the most widely used examination in the diagnosis and evaluation of CCC, and it is also employed in epidemiological surveys, risk stratification for cardiovascular events and death, and monitoring the clinical progression of the disease. Carlos Chagas and Eurico Villela published the first work addressing CCC in 1922. Other works followed, including the study by Evandro Chagas' which was the first to perform ECG in CD, culminating in Francisco Laranja's seminal work in 1956. Since the 1980s, standardizations and ECG reading codes for CD have been established. This standardization aimed to code complex arrhythmias and characteristic ventricular conduction disorders and standardize ECG readings for clinical and epidemiological studies in CD. Nearly all existing electrocardiographic abnormalities can be found in CD, with a predominance of abnormalities in the formation and conduction of cardiac stimuli. The complex and heterogeneous substrate of CD with varied electrocardiographic manifestations poses a significant challenge when comparing studies involving patients with CCC, emphasizing the need for ECG standardization in CD.


Asunto(s)
Cardiomiopatía Chagásica , Enfermedad de Chagas , Humanos , Cardiomiopatía Chagásica/diagnóstico , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/diagnóstico , Enfermedad de Chagas/epidemiología , Electrocardiografía , Enfermedad Crónica
10.
J Nucl Cardiol ; 30(6): 2702-2711, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37605061

RESUMEN

BACKGROUND: Chagas heart disease (CHD) is characterized by progressive myocardial inflammation associated with myocardial fibrosis and segmental abnormalities that may lead to malignant ventricular arrhythmia and sudden cardiac death. This arrhythmia might be related to the persistence of parasitemia or inflammation in the myocardium in late-stage CHD. Positron emission tomography/computed tomography (PET/CT) has been used to detect myocardial inflammation in non-ischemic cardiomyopathies, such as sarcoidosis, and might be useful for risk prediction in patients with CHD. METHODS AND RESULTS: Twenty-four outpatients with chronic CHD were enrolled in this prospective cross-sectional study between May 2019 and March 2022. The patients were divided into two groups: those with sustained ventricular tachycardia and/or aborted sudden cardiac death who required implantable cardioverter-defibrillators, and those with the same stages of CHD and no complex ventricular arrhythmia. Patients underwent 18F-fluorodeoxyglucose (18F-FDG) and 68Ga-DOTATOC PET/CT, and blood samples were collected for qualitative parasite assessment by polymerase chain reaction. Although similar proportions of patients with and without complex ventricular arrhythmia showed 18F-FDG and 68Ga-DOTATOC uptake, 68Ga-DOTATOC corrected SUVmax was higher in patients with complex arrhythmia (3.4 vs 1.7; P = .046), suggesting that inflammation could be associated with the presence of malignant arrhythmia in the late stages of CHD. We also detected Trypanosoma cruzi in both groups, with a nonsignificant trend of increased parasitemia in the group with malignant arrhythmia (66.7% vs 33.3%). CONCLUSION: 18F-FDG and 68Ga-DOTATOC uptake on PET/CT may be useful for the detection of myocardial inflammation in patients with Chagas cardiomyopathy, and 68Ga-DOTATOC uptake may be associated with the presence of malignant arrhythmia, with potential therapeutic implications.


Asunto(s)
Enfermedad de Chagas , Cardiopatías , Miocarditis , Humanos , Tomografía Computarizada por Tomografía de Emisión de Positrones , Fluorodesoxiglucosa F18 , Tomografía de Emisión de Positrones/métodos , Radioisótopos de Galio , Estudios Transversales , Parasitemia , Estudios Prospectivos , Miocarditis/diagnóstico por imagen , Arritmias Cardíacas/diagnóstico por imagen , Inflamación/diagnóstico por imagen , Muerte Súbita Cardíaca , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/diagnóstico por imagen
11.
Arq Bras Cardiol ; 120(6): e20230269, 2023 06 26.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-37377258
12.
J Nucl Cardiol ; 30(6): 2379-2388, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37226005

RESUMEN

BACKGROUND: Sudden cardiac death (SCD) can be the first clinical event of Chagas heart disease (CHD). However, current guidelines contain no clear recommendation for early cardioverter-defibrillator implantation. Using imaging modalities, we evaluated associations among autonomic denervation, myocardial hypoperfusion, fibrosis and ventricular arrhythmia in CHD. METHODS AND RESULTS: Twenty-nine patients with CHD and preserved left ventricular function underwent 123I-metaiodobenzylguanidine (MIBG) scintigraphy, 99mTc-methoxyisobutylisonitrile (MIBI) myocardial perfusion and cardiac magnetic resonance imaging (MRI). They were divided into arrhythmic (≥ 6 ventricular premature complexes/h and/or non-sustained ventricular tachycardia on 24-hour Holter, n = 15) and non-arrhythmic (< 6 ventricular premature complexes/h and no ventricular tachycardia; n = 14) groups. The arrhythmic group had higher denervation scores from MIBG imaging (23.2 ± 18.7 vs 5.6 ± 4.9; P < .01), hypoperfusion scores from MIBI SPECT (4.7 ± 6.8 vs 0.29 ± 0.6: P = .02), innervation/perfusion mismatch scores (18.5 ± 17.5 vs 5.4 ± 4.8; P = .01) and fibrosis by late gadolinium enhancement on MRI (14.3% ± 13.5% vs 4.0% ± 2.9%; P = .04) than the non-arrhythmic group. CONCLUSION: These imaging parameters were associated with ventricular arrhythmia in early CHD and may enable risk stratification and the implementation of primary preventive strategies for SCD.


Asunto(s)
Cardiomiopatía Chagásica , Enfermedad de Chagas , Enfermedad de la Arteria Coronaria , Isquemia Miocárdica , Complejos Prematuros Ventriculares , Humanos , Cardiomiopatía Chagásica/complicaciones , Cardiomiopatía Chagásica/diagnóstico por imagen , 3-Yodobencilguanidina , Medios de Contraste , Gadolinio , Muerte Súbita Cardíaca/prevención & control , Fibrosis , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/diagnóstico por imagen , Desnervación Autonómica
13.
Front Med (Lausanne) ; 10: 1031455, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36936214

RESUMEN

Diagnosis of Trypanosoma cruzi (T. cruzi) infection in the chronic phase of Chagas disease (CD) is performed by serologic testing. Conventional tests are currently used with very good results but require time, laboratory infrastructure, and expertise. Rapid diagnostic tests (RDTs) are an alternative as the results are immediate and do not require specialized knowledge, making them suitable for epidemiologic studies and promising as a screening tool. Nevertheless, few studies conducted comparative evaluations of RDTs to validate the results and assess their performance. In this study, we analyzed four trades of rapid tests (OnSite Chagas Ab Combo Rapid Test-United States, SD Bioline Chagas AB-United States, WL Check Chagas-Argentina, and TR Chagas Bio-Manguinhos-Brazil) using a panel of 190 samples, including sera from 111 infected individuals, most of whom had low T. cruzi antibody levels. An additional 59 samples from uninfected individuals and 20 sera from individuals with other diseases, mainly visceral leishmaniasis, were included. All tests were performed by three independent laboratories in a blinded manner. Results showed differences in sensitivity from 92.8 to 100%, specificity from 78.5 to 92.4%, and accuracy from 90.5 to 95.3% among the four assays. The results presented here show that all four RDTs have high overall diagnostic ability. However, WL Check Chagas and TR Chagas Bio-Manguinhos were considered most suitable for use in screening studies due to their high sensitivity combined with good performance. Although these two RDTs have high sensitivity, a positive result should be confirmed with other tests to confirm or rule out reactivity/positivity, especially considering possible cross-reactivity with individuals with leishmaniasis or toxoplasmosis.

14.
Disabil Rehabil ; 45(1): 51-56, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-35007459

RESUMEN

PURPOSE: The aim of the present study was to evaluate the effects of cardiovascular rehabilitation (CR) on functional capacity of patients with chronic chagasic cardiomyopathy (CCC) and to compare the responses between CCC patients without and with heart failure (HF). MATERIALS AND METHODS: A longitudinal observational retrospective study was carried out including 36 patients with CCC without HF (stage B2 [n = 7]) and with HF (stage C [n = 29]), who participated in a CR program. Functional capacity was assessed by a maximal progressive cardiopulmonary exercise test performed on a treadmill. The longitudinal effects of the CR on functional capacity were determined by linear mixed models that included an interaction term to evaluate the differential responses between patients without and with HF. RESULTS: Significant improvements in peak oxygen consumption, resting heart rate and blood pressure, and maximum pulmonary ventilation were observed for the overall study sample, with no apparent differential effects according to the presence of HF. CONCLUSIONS: CR significantly improved functional capacity of patients with CCC. The responses to CR appear to be similar among patients without and with HF, reinforcing the need for its inclusion as a standard treatment strategy of CCC.Implications for rehabilitationExercise-based cardiovascular rehabilitation (CR) is a safe strategy that improves functional capacity, cardiac function, and quality of life in patients with several cardiovascular diseases, and recent studies also suggested a potential beneficial effect of CR in chronic chagasic cardiomyopathy (CCC).In this observational study, CR seems to equally improve exercise capacity, resting heart rate, resting blood pressure, and maximum pulmonary ventilation in patients with CCC without (stage B2) and with heart failure (stage C).Cardiovascular rehabilitation should be included as a standard treatment strategy for patients with CCC, regardless the severity of cardiomyopathy.


Asunto(s)
Rehabilitación Cardiaca , Cardiomiopatías , Insuficiencia Cardíaca , Humanos , Calidad de Vida , Estudios Retrospectivos , Insuficiencia Cardíaca/complicaciones , Cardiomiopatías/etiología
15.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;56: e0506, 2023. tab
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1529506

RESUMEN

ABSTRACT Chagas disease (CD) remains one of the most significant endemic diseases in Latin America. Approximately 30% of individuals with CD develop the cardiac form, the main determinant of morbidity and mortality, which is characterized by typical electrocardiogram (ECG) changes caused by chronic chagasic cardiopathy (CCC). This review accentuates to how crucial it is for research teams and reference centers that treat patients with CD to standardize ECG in CCC. This was a non-systematic review of the literature. ECG is the most widely used examination in the diagnosis and evaluation of CCC, and it is also employed in epidemiological surveys, risk stratification for cardiovascular events and death, and monitoring the clinical progression of the disease. Carlos Chagas and Eurico Villela published the first work addressing CCC in 1922. Other works followed, including the study by Evandro Chagas' which was the first to perform ECG in CD, culminating in Francisco Laranja's seminal work in 1956. Since the 1980s, standardizations and ECG reading codes for CD have been established. This standardization aimed to code complex arrhythmias and characteristic ventricular conduction disorders and standardize ECG readings for clinical and epidemiological studies in CD. Nearly all existing electrocardiographic abnormalities can be found in CD, with a predominance of abnormalities in the formation and conduction of cardiac stimuli. The complex and heterogeneous substrate of CD with varied electrocardiographic manifestations poses a significant challenge when comparing studies involving patients with CCC, emphasizing the need for ECG standardization in CD.

16.
Rev. Soc. Bras. Med. Trop ; Rev. Soc. Bras. Med. Trop;56: e0389, 2023. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1529509

RESUMEN

ABSTRACT The increase in inflammatory markers associated with persistent chronic fibrosing myocarditis, a characteristic of chronic Chagas disease, can result in a reduction in inspiratory muscle strength (IMS) in Chagas cardiomyopathy (CC). However, literature in this field is still scarce. This review aimed to map and summarize the evidence regarding IMS in patients with CC. The inclusion criteria included reports with adult participants with a CC diagnosis, with or without heart failure (HF). The core concept examined was the maximum inspiratory pressure evaluated in the untrained and trained groups in the pre-training period. The context was open, including but not limited to hospitals and health centers. Two authors independently identified eligible studies and extracted the data. Descriptive synthesis was used as the primary strategy for analyzing the results. Nine studies (five clinical trials, three cross-sectional, and one cohort) were included. The CC classification differed among the studies, with no mention of HF in five and no CC staging specification in six. IMS was assessed using a manovacuometer, and only six studies analyzed and interpreted the data concerning the predicted values. The CC population with HF appeared to have impaired IMS. All studies involved only Brazilian volunteers. In conclusion, randomized clinical trials evaluating IMS and the effects of inspiratory muscle training need to be conducted to better understand the prevalence and risk of inspiratory muscle weakness in the CC population, as well as the effects of training. Such studies should be conducted at different stages of CC in different populations and countries.

18.
Marin-Neto, José Antonio; Rassi Jr, Anis; Oliveira, Gláucia Maria Moraes; Correia, Luís Claudio Lemos; Ramos Júnior, Alberto Novaes; Luquetti, Alejandro Ostermayer; Hasslocher-Moreno, Alejandro Marcel; Sousa, Andréa Silvestre de; Paola, Angelo Amato Vincenzo de; Sousa, Antônio Carlos Sobral; Ribeiro, Antonio Luiz Pinho; Correia Filho, Dalmo; Souza, Dilma do Socorro Moraes de; Cunha-Neto, Edecio; Ramires, Felix Jose Alvarez; Bacal, Fernando; Nunes, Maria do Carmo Pereira; Martinelli Filho, Martino; Scanavacca, Maurício Ibrahim; Saraiva, Roberto Magalhães; Oliveira Júnior, Wilson Alves de; Lorga-Filho, Adalberto Menezes; Guimarães, Adriana de Jesus Benevides de Almeida; Braga, Adriana Lopes Latado; Oliveira, Adriana Sarmento de; Sarabanda, Alvaro Valentim Lima; Pinto, Ana Yecê das Neves; Carmo, Andre Assis Lopes do; Schmidt, Andre; Costa, Andréa Rodrigues da; Ianni, Barbara Maria; Markman Filho, Brivaldo; Rochitte, Carlos Eduardo; Macêdo, Carolina Thé; Mady, Charles; Chevillard, Christophe; Virgens, Cláudio Marcelo Bittencourt das; Castro, Cleudson Nery de; Britto, Constança Felicia De Paoli de Carvalho; Pisani, Cristiano; Rassi, Daniela do Carmo; Sobral Filho, Dário Celestino; Almeida, Dirceu Rodrigues de; Bocchi, Edimar Alcides; Mesquita, Evandro Tinoco; Mendes, Fernanda de Souza Nogueira Sardinha; Gondim, Francisca Tatiana Pereira; Silva, Gilberto Marcelo Sperandio da; Peixoto, Giselle de Lima; Lima, Gustavo Glotz de; Veloso, Henrique Horta; Moreira, Henrique Turin; Lopes, Hugo Bellotti; Pinto, Ibraim Masciarelli Francisco; Ferreira, João Marcos Bemfica Barbosa; Nunes, João Paulo Silva; Barreto-Filho, José Augusto Soares; Saraiva, José Francisco Kerr; Lannes-Vieira, Joseli; Oliveira, Joselina Luzia Menezes; Armaganijan, Luciana Vidal; Martins, Luiz Cláudio; Sangenis, Luiz Henrique Conde; Barbosa, Marco Paulo Tomaz; Almeida-Santos, Marcos Antonio; Simões, Marcos Vinicius; Yasuda, Maria Aparecida Shikanai; Moreira, Maria da Consolação Vieira; Higuchi, Maria de Lourdes; Monteiro, Maria Rita de Cassia Costa; Mediano, Mauro Felippe Felix; Lima, Mayara Maia; Oliveira, Maykon Tavares de; Romano, Minna Moreira Dias; Araujo, Nadjar Nitz Silva Lociks de; Medeiros, Paulo de Tarso Jorge; Alves, Renato Vieira; Teixeira, Ricardo Alkmim; Pedrosa, Roberto Coury; Aras Junior, Roque; Torres, Rosalia Morais; Povoa, Rui Manoel dos Santos; Rassi, Sergio Gabriel; Alves, Silvia Marinho Martins; Tavares, Suelene Brito do Nascimento; Palmeira, Swamy Lima; Silva Júnior, Telêmaco Luiz da; Rodrigues, Thiago da Rocha; Madrini Junior, Vagner; Brant, Veruska Maia da Costa; Dutra, Walderez Ornelas; Dias, João Carlos Pinto.
Arq. bras. cardiol ; Arq. bras. cardiol;120(6): e20230269, 2023. tab, graf
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1447291
19.
PLoS One ; 17(12): e0279086, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36520825

RESUMEN

Studies investigating the association between functional capacity and quality of life (QoL) in individuals with chronic Chagas cardiomyopathy (CCC) usually do not include a gold-standard evaluation of functional capacity, limiting the validity and the interpretation of the results. The present study is a cross-section analysis aiming to evaluate the association between functional capacity (quantified by cardiopulmonary exercise test [CPET]) and QoL in individuals with CCC. QoL was assessed using the SF-36 questionnaire. Sociodemographic, anthropometric, clinical, cardiac function and maximal progressive CPET variables were obtained from PEACH study. Generalized linear models adjusted for age, sex, and left ventricular ejection fraction were performed to evaluate the association between CPET variables and QoL. After adjustments, VO2 peak and VO2 AT were both associated with physical functioning (ß = +0.05 and ß = +0.05, respectively) and physical component summary (ß = +0.03 and ß = +0.03, respectively). Double product was associated with physical functioning (ß = +0.003), general health perceptions (ß = +0.003), physical component summary (ß = +0.002), and vitality (ß = +0.004). HRR≤12bpm was associated with physical functioning (ß = -0.32), role limitations due to physical problems (ß = -0.87), bodily pain (ß = -0.26), physical component summary (ß = -0.21), vitality (ß = -0.38), and mental health (ß = -0.19). VE/VCO2 slope presented association with all mental scales of SF-36: vitality (ß = -0.028), social functioning (ß = -0.024), role limitations due to emotional problems (ß = -0.06), mental health (ß = -0.04), and mental component summary (ß = -0.02). The associations between CPET variables and QoL demonstrate the importance of CPET inclusion for a more comprehensive evaluation of individuals with CCC. In this setting, intervention strategies aiming to improve functional capacity may also promote additional benefits on QoL and should be incorporated as a treatment strategy for patients with CCC.


Asunto(s)
Cardiomiopatía Chagásica , Prueba de Esfuerzo , Humanos , Prueba de Esfuerzo/métodos , Calidad de Vida/psicología , Volumen Sistólico , Función Ventricular Izquierda , Consumo de Oxígeno
20.
Rev Soc Bras Med Trop ; 55: e02402022, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36287507

RESUMEN

BACKGROUND: The recent urbanization of Chagas disease (CD) has contributed to a greater risk of coexistence with human immunodeficiency virus (HIV) and AIDS. METHODS: This retrospective observational study included patients who were followed at INI-Fiocruz between July 1986 and October 2021. All patients underwent an assessment protocol that included sociodemographic profile, epidemiological history, and clinical evaluation. Descriptive data analyses included reports of the medians and frequencies of variables of interest. Differences in medians between groups were tested using the Mann-Whitney U test. Differences in frequency were tested using Fisher's exact test. RESULTS: Among 2201 patients, 11 (0.5%) were identified with Trypanosoma cruzi/HIV coinfection. Of these, 63.6% were women with a median age of 51.0 years old. Two patients had the indeterminate form of CD, six had the cardiac form, two had the digestive form and one had the cardio-digestive form. Half of the patients were undergoing antiretroviral treatment at the time of coinfection diagnosis with a median CD4+ count of 350 cells/µL and a viral load of 1500 copies/µL. Four patients underwent a xenodiagnosis test at coinfection diagnosis, which all yielded positive results; two of them presented high parasitemia under the risk of reactivation. Prophylaxis for CD reactivation was administered to four patients; two with ketoconazole and two with benznidazole. Six patients died after a median follow-up of 22.5 months, with AIDS being the most common cause of death. Only one case of reactivation was observed. CONCLUSIONS: Early diagnosis and prompt treatment of CD reactivation dramatically reduced mortality. Identification of Trypanosoma cruzi/HIV co-infection is crucial to planning a close follow-up of coinfected patients.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida , Enfermedad de Chagas , Coinfección , Infecciones por VIH , Trypanosoma cruzi , Humanos , Femenino , Persona de Mediana Edad , Masculino , Trypanosoma cruzi/fisiología , Infecciones por VIH/complicaciones , Infecciones por VIH/epidemiología , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Brasil/epidemiología , Cetoconazol/uso terapéutico , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA